Loading...
Market
What will be the outcome of the first clinical data from the Novartis and Generate:Biomedicines partnership reported by December 31, 2024?
2
Resolution / Starting Odds
Positive • 25%
Negative • 25%
Neutral • 25%
Not Reported • 25%
Official press releases or scientific publications
Story
Novartis Partners with Generate:Biomedicines in AI Drug Development Deal Worth Over $1 Billion, $65 Million Upfront
Sep 24, 2024, 12:46 PM
Novartis has entered into a significant partnership with Generate:Biomedicines, a company founded by Flagship Pioneering, to leverage generative AI for the discovery and development of protein therapeutics. The deal includes an upfront payment of $65 million to Generate:Biomedicines, with potential milestone payments that could exceed $1 billion. This collaboration aims to develop protein therapeutics for multiple unspecified disease areas. Generate:Biomedicines' CEO Mike Nally indicated that this deal will bring the company's cash balance to over $350 million. Novartis' commitment to utilizing AI tools for accelerating drug discovery and development is further highlighted by this partnership. Clinical data is expected soon in Covid and TSLP, with more antibodies headed to the clinic.
View original story
Similar markets
Completed with positive results • 25%
Completed with negative results • 25%
Not completed • 25%
Unknown/Other • 25%
Respiratory drug • 25%
Immunology drug • 25%
Vaccine • 25%
Other • 25%
Significant efficacy • 25%
Moderate efficacy • 25%
No efficacy • 25%
Inconclusive results • 25%
Successful with no major adverse effects • 25%
Successful with minor adverse effects • 25%
Unsuccessful due to lack of efficacy • 25%
Unsuccessful due to major adverse effects • 25%
Yes • 50%
No • 50%
Successful • 33%
Partially Successful • 33%
Unsuccessful • 33%
Complete Response (CR) • 25%
Partial Response (PR) • 25%
Stable Disease (SD) • 25%
Progressive Disease (PD) • 25%
Yes • 50%
No • 50%
Positive results • 25%
Negative results • 25%
Mixed results • 25%
No results announced • 25%
Significant improvement • 25%
Moderate improvement • 25%
No improvement • 25%
Worsening condition • 25%
